Sera Prognostics, a company focused on improving maternal and neonatal health through innovative precision biomarker approaches, together with leading health benefits company Anthem and its HealthCore subsidiary, an evidence generation company, have launched and started to enroll patients in a study to determine whether a test, along with clinical interventions, can lead to improved health for newborns and mothers. The primary objective…
